Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma.
Lists
Only you see this
Abstract
CHOP alone could be as effective as R-CHOP regimen and additional radiotherapy would be necessary for stage I or stage I non-bulky DLBCL patients.
BibTeX
@inproceedings{jia2015addition,
author = {Bo Jia and Yuankai Shi and Suyi Kang and Sheng Yang and Shaoxuan Hu and Ye‐Xiong Li and Mei Dong and Weihu Wang and Jianliang Yang and Liqiang Zhou and Peng Liu and Shengyu Zhou and Yan Qin and Lin Gui and Changgong Zhang and Hua Lin and Shanshan Chen and Lin Wang and Xiaohui He},
title = {{Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma.}},
booktitle = {PubMed},
year = {2015},
doi = {10.3978/j.issn.1000-9604.2015.10.04},
}Loading related content...